US 12,291,574 B2
Pooled NK cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease
Patrick Henno, Saint Mathieu-de-Treviers (FR)
Assigned to EMERCELL SAS, Saint Mathieu-de-Treviers (FR)
Filed by EMERCELL SAS, Saint Mathieu-de-Treviers (FR)
Filed on Oct. 13, 2021, as Appl. No. 17/500,874.
Application 17/500,874 is a continuation of application No. 15/458,680, filed on Mar. 14, 2017, abandoned.
Application 15/458,680 is a continuation in part of application No. PCT/EP2016/071470, filed on Sep. 12, 2016.
Claims priority of application No. 15306403 (EP), filed on Sep. 11, 2015.
Prior Publication US 2022/0096554 A1, Mar. 31, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/32 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01)
CPC C07K 16/2887 (2013.01) [A61K 39/3955 (2013.01); A61K 39/4613 (2023.05); A61K 39/464424 (2023.05); C07K 16/30 (2013.01); C07K 16/3069 (2013.01); C07K 16/32 (2013.01); C12N 5/0646 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/92 (2013.01)] 17 Claims
 
1. A method for treating cancer comprising the administration to a subject in need of treatment for cancer of a therapeutically effective amount of a first composition and a second composition, wherein
said first composition comprising a population of alloreactive natural killer cells (NK cells) which are derived from a mixture of at least n umbilical cord blood units (UCB units) pooled from two or more different donors, or a mixture of fraction thereof containing said NK cells, with n≥2; and
said second composition comprising a monoclonal antibody or a specific binding fragment thereof directed to a cell receptor antigen of cells of said subject;
wherein the population of alloreactive NK cells comprised in said first composition are obtained by a method comprising:
(A) providing at least n umbilical cord blood units (UCB units), or fraction thereof, each UCB unit or fraction thereof comprising NK cells and T cells, with n≥2;
(B) pooling said at least n UCB units from two or more different donors, or pooled fraction thereof, and depleting said T cells to produce the population of cells comprising pooled NK cells;
(C) expanding and activating said pooled NK cells in a medium comprising accessory cells to produce a population of expanded activated NK cells; and
(D) recovering said expanded activated NK cells; and
wherein the pattern for major HLA class I groups genotype is the same in each of said n UCB units pooled from two or more different donors, or pooled fraction thereof, and is selected from the group consisting of HLA A3/A11, which is recognized by KIR3DL2; HLA Bw4, which recognized by KIR3DL1; HLA C group 1, which is recognized by KIR2DL2/3; and HLA C group 2, which is recognized by KIR2DL1; and
wherein in step (C) said pooled NK cells and said accessory cells are HLA-KIR mismatched.